Could Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Go Up After Its Newest Short Interest Report?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Logo

Investors sentiment decreased to 1.84 in Q2 2019. Its down 0.02, from 1.86 in 2019Q1. It worsened, as 24 investors sold Intercept Pharmaceuticals, Inc. shares while 34 reduced holdings. 28 funds opened positions while 79 raised stakes. 24.97 million shares or 33.57% less from 37.59 million shares in 2019Q1 were reported.
7,954 were accumulated by Private Capital Advsrs Inc. Moreover, Northwestern Mutual Wealth Mgmt has 0% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 186 shares. Citigroup reported 36,459 shares or 0% of all its holdings. Hap Trading Limited Liability, a New York-based fund reported 13,962 shares. The United Kingdom-based Barclays Plc has invested 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Smith Asset Mgmt Gru L P invested 0% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Samlyn Ltd Company stated it has 226,628 shares. Asset Mgmt Inc reported 16,240 shares stake. Ing Groep Nv reported 0.01% stake. Jennison Assocs Limited Company stated it has 0.01% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Moreover, Vanguard Grp has 0.01% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Ameriprise Fin has invested 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Pinnacle Assocs owns 129,815 shares for 0.24% of their portfolio. Fifth Third National Bank & Trust owns 736 shares. Raymond James stated it has 2,982 shares.

The stock of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) registered an increase of 5.03% in short interest. ICPT’s total short interest was 5.71 million shares in September as published by FINRA. Its up 5.03% from 5.43M shares, reported previously. With 814,200 shares average volume, it will take short sellers 7 days to cover their ICPT’s short positions. The short interest to Intercept Pharmaceuticals Inc’s float is 25.61%.

The stock increased 0.81% or $0.55 during the last trading session, reaching $68.62. About 381,706 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has declined 29.32% since September 13, 2018 and is downtrending. It has underperformed by 29.32% the S&P500.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The company has market cap of $2.24 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). It currently has negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Ratings Coverage

Among 4 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Intercept Pharmaceuticals has $18600 highest and $8500 lowest target. $116’s average target is 69.05% above currents $68.62 stock price. Intercept Pharmaceuticals had 8 analyst reports since April 12, 2019 according to SRatingsIntel. The firm has “Overweight” rating given on Thursday, August 8 by Cantor Fitzgerald. The firm has “Market Perform” rating by Wells Fargo given on Friday, April 12. The stock has “Hold” rating by Stifel Nicolaus on Monday, June 24. The firm earned “Buy” rating on Wednesday, September 4 by Citigroup.

More notable recent Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) news were published by: which released: “Intercept Pharmaceuticals Enters Oversold Territory (ICPT) – Nasdaq” on July 19, 2019, also with their article: “Investors Who Bought Intercept Pharmaceuticals (NASDAQ:ICPT) Shares Five Years Ago Are Now Down 79% – Yahoo Finance” published on August 08, 2019, published: “Intercept Pharmaceuticals Announces Proposed Offerings of $200 Million of Common Stock and $200 Million of Convertible Senior Notes due 2026 – GlobeNewswire” on May 08, 2019. More interesting news about Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) were released by: and their article: “Here’s What Hedge Funds Think About Intercept Pharmaceuticals Inc (ICPT) – Yahoo Finance” published on April 26, 2019 as well as‘s news article titled: “What You’ll Want to Know About Intercept Pharmaceuticals’ Q2 Update – Yahoo Finance” with publication date: August 07, 2019.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.